UY35624A - Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington - Google Patents

Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington

Info

Publication number
UY35624A
UY35624A UY35624A UY35624A UY35624A UY 35624 A UY35624 A UY 35624A UY 35624 A UY35624 A UY 35624A UY 35624 A UY35624 A UY 35624A UY 35624 A UY35624 A UY 35624A
Authority
UY
Uruguay
Prior art keywords
disease
pridopidine
high dose
treat huntington
huntington
Prior art date
Application number
UY35624A
Other languages
English (en)
Inventor
Bassan Merav
Esther Lukasiewicz Hagai
Eyal Eli
Anna Kristina Sveinsdotter Teige Wickenberg
Original Assignee
Ivax Int Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52105289&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY35624(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ivax Int Gmbh filed Critical Ivax Int Gmbh
Publication of UY35624A publication Critical patent/UY35624A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

Método de tratamiento de un paciente humano que sufre de la enfermedad de Huntington, que comprende administrar periódicamente por vía oral al paciente una composición farmacéutica que comprende pridopidina o una sal farmacéuticamente aceptable de la misma de manera tal que se administren más de 90 mg de pridopidina a dicho paciente por día
UY35624A 2013-06-21 2014-06-23 Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington UY35624A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361837928P 2013-06-21 2013-06-21
US201361877832P 2013-09-13 2013-09-13

Publications (1)

Publication Number Publication Date
UY35624A true UY35624A (es) 2015-01-30

Family

ID=52105289

Family Applications (1)

Application Number Title Priority Date Filing Date
UY35624A UY35624A (es) 2013-06-21 2014-06-23 Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington

Country Status (24)

Country Link
US (1) US10322119B2 (es)
EP (1) EP3010506B1 (es)
JP (1) JP2016523862A (es)
KR (1) KR102316933B1 (es)
CN (1) CN105592848A (es)
AU (1) AU2014281414A1 (es)
BR (1) BR112015029918A2 (es)
CA (1) CA2913781C (es)
CL (1) CL2015003690A1 (es)
DK (1) DK3010506T3 (es)
EA (1) EA201690069A1 (es)
ES (1) ES2879631T3 (es)
HK (1) HK1221646A1 (es)
HU (1) HUE054783T2 (es)
IL (1) IL242804B (es)
MX (1) MX2015017307A (es)
PE (2) PE20160195A1 (es)
PH (1) PH12015502691A1 (es)
PL (1) PL3010506T3 (es)
SG (1) SG11201509729YA (es)
TW (1) TW201529069A (es)
UA (1) UA122999C2 (es)
UY (1) UY35624A (es)
WO (1) WO2014205229A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
CA2810092A1 (en) 2010-09-03 2012-03-08 IVAX International GmbH Deuterated analogs of pridopidine useful as dopaminergic stabilizers
US9012476B2 (en) 2011-12-08 2015-04-21 IVAX International GmbH Hydrobromide salt of pridopidine
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
US20150202302A1 (en) * 2014-01-22 2015-07-23 IVAX International GmbH Modified release formulations of pridopidine
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
WO2016106142A1 (en) 2014-12-22 2016-06-30 Teva Pharmaceuticals International Gmbh L-tartrate salt of pridopidine
HUE060353T2 (hu) * 2015-02-25 2023-02-28 Prilenia Neurotherapeutics Ltd Pridopidin alkalmazása memória javítására
US11471449B2 (en) 2015-02-25 2022-10-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
CA2993183A1 (en) * 2015-07-22 2017-01-26 Teva Pharmaceuticals International Gmbh Pridopidine base formulations and their use
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
US11738012B2 (en) 2016-02-24 2023-08-29 Prilenia Neurotherapeutics Ltd. Treatment of neurodegenerative eye disease using pridopidine
EP3504187A4 (en) * 2016-08-24 2020-05-06 Prilenia Neurotherapeutics Ltd. USE OF PRIDOPIDINE FOR THE TREATMENT OF FUNCTIONAL DECLINE
MX2019002190A (es) * 2016-08-24 2019-09-11 Prilenia Therapeutics Dev Ltd Uso de pridopidina para tratar distonías.
WO2018053287A1 (en) * 2016-09-15 2018-03-22 Teva Pharmaceuticals International Gmbh Use of pridopidine for the treatment of anxiety and depression
CA3036984C (en) 2016-09-16 2023-07-18 Prilenia Therapeutics Development Ltd. Use of pridopidine for treating rett syndrome
CN110505902B (zh) 2017-01-20 2022-11-11 普瑞尼亚神经治疗有限公司 普利多匹定用于治疗脆性x综合征的应用
EP3668509B1 (en) 2017-08-14 2022-11-16 Prilenia Neurotherapeutics Ltd. Method of treating amyotrophic lateral sclerosis with pridopidine
CA3073568A1 (en) 2017-08-30 2019-03-07 Prilenia Neurotherapeutics Ltd. High concentration dosage forms of pridopidine
CN111343982A (zh) 2017-09-08 2020-06-26 普瑞尼亚神经治疗有限公司 用于治疗药物诱发的异动症的普利多匹定
WO2020250234A1 (en) * 2019-06-12 2020-12-17 Prilenia Neurotherapeutics Ltd. Composition comprising pridopidine and analog thereof for treating huntington disease and symptoms thereof
WO2021055443A1 (en) * 2019-09-17 2021-03-25 Hoffmann-La Roche Inc. Improvements in personalized healthcare for patients with movement disorders
US20230390232A1 (en) * 2020-10-28 2023-12-07 Buck Institute For Research On Aging N-propargylglycine: a unique inhibitor of proline dehydrogenase with brain-enhancing mitohormesis properties capable of mitigating the pathogenesis of neurodegenerative disorders

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
SE9904724D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
EP1713486A4 (en) 2003-12-02 2009-04-29 Sheldon Leslie James COMBINED THERAPY FOR THE TREATMENT OF DEMENTIA, DEPRESSION AND APATHY
WO2006040155A1 (en) 2004-10-13 2006-04-20 Neurosearch Sweden Ab Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-n-propyl-piperidine
EP1815857A1 (en) * 2006-02-02 2007-08-08 LEK Pharmaceuticals D.D. A pharmaceutical composition comprising perindopril
PT2146961E (pt) 2007-04-12 2014-04-30 Ivax Int Gmbh Derivados de n-óxido e/ou di-n-óxido de estabilizadores / moduladores dos recetores da dopamina exibindo perfis de efeitos secundários cardiovasculares melhorados
WO2010008486A2 (en) 2008-06-24 2010-01-21 Parkinsons Institute Pluripotent cell lines and methods of use thereof
US8384755B2 (en) 2009-08-26 2013-02-26 Intouch Technologies, Inc. Portable remote presence robot
US20110206782A1 (en) * 2010-02-24 2011-08-25 Auspex Pharmaceuticals, Inc. Piperidine modulators of dopamine receptor
WO2011107583A1 (en) * 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
CA2810092A1 (en) 2010-09-03 2012-03-08 IVAX International GmbH Deuterated analogs of pridopidine useful as dopaminergic stabilizers
EA023462B1 (ru) 2011-09-07 2016-06-30 Тева Фармасьютикалз Интернэшнл Гмбх Полиморфная форма гидрохлорида придопидина
US9012476B2 (en) 2011-12-08 2015-04-21 IVAX International GmbH Hydrobromide salt of pridopidine
US9744155B2 (en) 2012-03-28 2017-08-29 Ixcela, Inc. IPA as a therapeutic agent, as a protective agent, and as a biomarker of disease risk
CA2869145A1 (en) 2012-04-04 2013-10-10 IVAX International GmbH Pharmaceutical compositions for combination therapy
EP2900226A4 (en) 2012-09-27 2016-03-30 Teva Pharma COMBINATION OF RASAGILIN AND PRIDOPIDIN FOR TREATING NEURODEGENERATIVE DISORDERS, ESPECIALLY HUNTINGTON'S DISEASE
US20140088140A1 (en) 2012-09-27 2014-03-27 Teva Pharmaceutical Industries, Ltd. Combination of laquinimod and pridopidine for treating neurodegenerative disorders, in particular huntington's disease
US20150202302A1 (en) 2014-01-22 2015-07-23 IVAX International GmbH Modified release formulations of pridopidine
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
WO2016106142A1 (en) 2014-12-22 2016-06-30 Teva Pharmaceuticals International Gmbh L-tartrate salt of pridopidine
HUE060353T2 (hu) 2015-02-25 2023-02-28 Prilenia Neurotherapeutics Ltd Pridopidin alkalmazása memória javítására
WO2016138135A1 (en) 2015-02-25 2016-09-01 Teva Pharmaceuticals International Gmbh Sigma-1 receptor modulators for treating huntington's disease
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
CA2993183A1 (en) 2015-07-22 2017-01-26 Teva Pharmaceuticals International Gmbh Pridopidine base formulations and their use
WO2017048457A1 (en) 2015-09-18 2017-03-23 Teva Pharmaceuticals Industries Ltd. Combination of laquinimod and pridopidine to treat multiple sclerosis
MX2019002190A (es) 2016-08-24 2019-09-11 Prilenia Therapeutics Dev Ltd Uso de pridopidina para tratar distonías.
EP3504187A4 (en) 2016-08-24 2020-05-06 Prilenia Neurotherapeutics Ltd. USE OF PRIDOPIDINE FOR THE TREATMENT OF FUNCTIONAL DECLINE
WO2018053287A1 (en) 2016-09-15 2018-03-22 Teva Pharmaceuticals International Gmbh Use of pridopidine for the treatment of anxiety and depression
CA3036984C (en) 2016-09-16 2023-07-18 Prilenia Therapeutics Development Ltd. Use of pridopidine for treating rett syndrome
WO2018053275A1 (en) 2016-09-16 2018-03-22 Teva Pharmaceuticals International Gmbh Use of pridopidine for the treatment of familial dysautonomia

Also Published As

Publication number Publication date
PL3010506T3 (pl) 2021-11-02
PE20160195A1 (es) 2016-05-14
CA2913781A1 (en) 2014-12-24
SG11201509729YA (en) 2015-12-30
US10322119B2 (en) 2019-06-18
HK1221646A1 (zh) 2017-06-09
PE20170302A1 (es) 2017-03-31
ES2879631T3 (es) 2021-11-22
WO2014205229A8 (en) 2015-04-09
UA122999C2 (uk) 2021-02-03
KR20160055122A (ko) 2016-05-17
CL2015003690A1 (es) 2016-10-28
BR112015029918A2 (pt) 2017-07-25
PH12015502691A1 (en) 2016-03-14
EP3010506A4 (en) 2017-02-08
WO2014205229A1 (en) 2014-12-24
CA2913781C (en) 2022-05-10
JP2016523862A (ja) 2016-08-12
DK3010506T3 (da) 2021-07-12
TW201529069A (zh) 2015-08-01
IL242804B (en) 2022-02-01
MX2015017307A (es) 2016-08-03
AU2014281414A1 (en) 2016-01-21
EP3010506A1 (en) 2016-04-27
EA201690069A1 (ru) 2016-06-30
KR102316933B1 (ko) 2021-10-26
EP3010506B1 (en) 2021-05-12
CN105592848A (zh) 2016-05-18
HUE054783T2 (hu) 2021-09-28
US20140378508A1 (en) 2014-12-25

Similar Documents

Publication Publication Date Title
UY35624A (es) Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington
PE20150161A1 (es) Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple
NI201100147A (es) Métodos para tratar infartos agudos de miocardio y trastornos relacionados.
MX2022003072A (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
CO2018004776A2 (es) Composiciones terapéuticas para el tratamiento del virus de inmunodeficiencia humana
EA201290026A1 (ru) Способ лечения пациента, имеющего риск развития язвы, связанной с приемом нестероидных противовоспалительных средств (nsaid)
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
PE20142319A1 (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero
CL2011002858A1 (es) Uso de una composicion farmaceutica transmucosa oral que comprende dexmedetomidina y una sal farmaceuticamente aceptable y un excipiente farmaceuticamente aceptable para preparar un medicamento util para tratar o prevenir el dolor.
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
EA201270071A1 (ru) Способ лечения пациента, нуждающегося в аспириновой терапии
MX2022015629A (es) Uso de vibegron para tratar vejiga sobreactiva.
UY35890A (es) Uso de laquinimod para retrasar la progresión de la enfermedad de huntington
AR099299A1 (es) Inhibidor de la proteína de transferencia de éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden dicho inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares
AR088845A1 (es) Composiciones farmaceuticas que contienen 7-(1h-imidazol-4-ilmetil)-5,6,7,8-tetrahidro-quinolina para el tratamiento de las enfermedades y las afecciones de la piel
CO2018009543A2 (es) Composición farmacéutica de liberación prolongada que comprende cisteamina o sal de la misma
AR074246A1 (es) Derivados de 1-amino-alquilciclohexano para el tratamiento de trastornos del sueno
MX2021007324A (es) Terapia oral con acido 6,8-bis-benciltio-octanoico.
DK2091520T3 (da) Oral doseringsform omfattende trisubstituerede glycerol-forbindelser
AR076016A1 (es) Domperidona a una dosis diaria baja para su uso en el tratamiento o la prevencion de una enfermedad asociada a una alteracion de la respuesta inmunitaria
AR104427A1 (es) Composiciones farmacéuticas para terapia de combinación
AR096674A1 (es) Método de tratamiento de un paciente humano que sufre de la enfermedad de huntington
EA201992690A1 (ru) Применение вибегрона для лечения гиперактивного мочевого пузыря
EA201990553A1 (ru) Применение придопидина для лечения ухудшения функциональной способности
CU20180036A7 (es) Composiciones terapéuticas para el tratamiento del virus de la inmunodeficiencia humana

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20211206